Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain
- PMID: 40796685
- DOI: 10.1038/s41584-025-01280-3
Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain
Abstract
Pain is the primary complaint in individuals with osteoarthritis (OA) and changes as the disease progresses. Anatomical changes in several joint structures potentially contribute to pain, including the increased innervation of the periosteum, synovium and subchondral bone, and the pathological innervation of articular cartilage, which is aneural under physiological conditions. Research has focused on molecules that sensitize afferent neurons, such as neuropeptides, neurotrophins, pro-inflammatory cytokines and ion channels. The neurotrophin nerve growth factor (NGF) is the best validated target in OA pain, with proven analgesic effects in preclinical and clinical studies, although the development of NGF-targeted therapeutics has been hampered by serious side effects. One relatively neglected area of research is the contribution to OA pain of the molecular pathways that mediate remodelling of nerves in disease. Remodelling requires coordination between the nerve and the associated vasculature, along with signals that are received from the surrounding parenchyma. Key cell guidance molecules, including angiogenic factors, ephrins, semaphorins and SLIT proteins are involved in nerve growth during development, and their expression is increased in osteoarthritic joints.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: T.L.V. has received research support for STEpUP OA from Biosplice, Fidia, Galapagos, GSK, Novartis, Pfizer and UCB, and has performed ad hoc consultancy for Zoetis 2024. M.Z.C. is Founder and Director of Oxford StemTech Ltd, Human-Cetric DD Ltd, has performed Consultancy and received Honoraria from AbbVie, Brandon Capital, Pfizer, TEVA, has received research support from GSK; and public–private partnership funding for the IM2PACT project. V.B. and T.A.P. declare no competing interests.
References
-
- Safiri, S. et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the global burden of disease study 2017. Ann. Rheum. Dis. 79, 819–828 (2020). - PubMed
-
- Hunter, D. J., March, L. & Chew, M. Osteoarthritis in 2020 and beyond: a Lancet commission. Lancet 396, 1711–1712 (2020). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
